K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that Mr. Robert Baldini was appointed as a new independent member of the Board of Directors by a unanimous vote of the directors, which also voted to increase the size of the Board to eight directors.
Mr. Joseph Lehrer, Chairman of the Board's Nominating and Corporate Governance Committee, stated, "The entire Board takes great pleasure in announcing that Mr. Robert Baldini has joined K-V as a member of its Board of Directors. Bob possesses an outstanding reputation within the pharmaceutical industry, as well as extensive knowledge and experience in sales, marketing and development of pharmaceutical products. We believe he will be an especially valuable asset to K-V as we continue to work towards receiving U.S. Food and Drug Administration approval of Gestiva(TM) and ultimately commence the launch and sales program for that product."
Mr. Baldini stated, "I am pleased to be invited to serve on the K-V Board because I want to be a part of the Company's resurgence. Over the course of my tenure as a Board member, I will utilize my background and experience in the pharmaceutical industry to assist management with respect to its current products, its launch of Gestiva(TM) following FDA approval, and the acquisition and development of other new pharmaceutical products."
No comments:
Post a Comment